CN114599428A - 双功能化合物 - Google Patents

双功能化合物 Download PDF

Info

Publication number
CN114599428A
CN114599428A CN202080074772.3A CN202080074772A CN114599428A CN 114599428 A CN114599428 A CN 114599428A CN 202080074772 A CN202080074772 A CN 202080074772A CN 114599428 A CN114599428 A CN 114599428A
Authority
CN
China
Prior art keywords
formula
absent
group
title compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074772.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·高福赫托
R·赫特
E·乔夫切瓦
B·库恩
T·利贝斯
R·E·马丁
L·J·马丁
B·J·穆勒
R·诺克罗斯
F·里克林
P·施密德
J-y·瓦克
J·维希曼
M·杜普莱西斯
K·拉扎斯基
梁焱科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
C4 Therapeutics Inc
Original Assignee
F Hoffmann La Roche AG
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, C4 Therapeutics Inc filed Critical F Hoffmann La Roche AG
Publication of CN114599428A publication Critical patent/CN114599428A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080074772.3A 2019-10-28 2020-10-26 双功能化合物 Pending CN114599428A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19205545 2019-10-28
EP19205545.7 2019-10-28
PCT/US2020/057356 WO2021086785A1 (en) 2019-10-28 2020-10-26 Bifunctional compounds

Publications (1)

Publication Number Publication Date
CN114599428A true CN114599428A (zh) 2022-06-07

Family

ID=68382246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074772.3A Pending CN114599428A (zh) 2019-10-28 2020-10-26 双功能化合物

Country Status (5)

Country Link
US (1) US20230002367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054724A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023511471A (cg-RX-API-DMAC7.html)
CN (1) CN114599428A (cg-RX-API-DMAC7.html)
WO (1) WO2021086785A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024002375A1 (zh) * 2022-06-30 2024-01-04 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025502782A (ja) * 2021-12-28 2025-01-28 ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム がん治療剤としての強力かつ選択的なsmarca2分解キメラ分子
JP2025506452A (ja) * 2022-02-09 2025-03-11 オーリジーン オンコロジー リミテッド Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
AU2023292503A1 (en) * 2022-06-15 2024-10-31 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
WO2024064328A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
WO2025096976A1 (en) * 2023-11-01 2025-05-08 Cornell University Arid1a is a prognostic marker for aggressive lymphoma transformation and presents a vulnerability to pharmacological inhibition of smarca4/2
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CN112771038A (zh) * 2018-04-26 2021-05-07 奥里吉恩发现科技有限公司 作为smarca2/4降解剂的哒嗪衍生物
CN114375192A (zh) * 2019-09-12 2022-04-19 奥瑞基尼探索技术有限公司 鉴定smarca2/4降解剂的应答者的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CN112771038A (zh) * 2018-04-26 2021-05-07 奥里吉恩发现科技有限公司 作为smarca2/4降解剂的哒嗪衍生物
CN114375192A (zh) * 2019-09-12 2022-04-19 奥瑞基尼探索技术有限公司 鉴定smarca2/4降解剂的应答者的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KWOK-HO CHAN,等: "Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 61, no. 2, pages 504 - 513, XP055930443, DOI: 10.1021/acs.jmedchem.6b01912 *
SAMUEL H. YALKOWSKY,等: "Correlation and Prediction of Mass Transport across Membranes 11: Influence of Vehicle Polarity on Flux from Solutions and Suspensions", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 63, no. 8, pages 1276 - 1280 *
WILLIAM FARNABY,等: "BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design", 《NAT URE CHEMICA L BIOLOGY》, vol. 15, pages 672, XP036824718, DOI: 10.1038/s41589-019-0294-6 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024002375A1 (zh) * 2022-06-30 2024-01-04 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用

Also Published As

Publication number Publication date
WO2021086785A1 (en) 2021-05-06
EP4054724A1 (en) 2022-09-14
US20230002367A1 (en) 2023-01-05
JP2023511471A (ja) 2023-03-20
EP4054724A4 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
JP2023511471A (ja) 二官能性化合物
CN114728936A (zh) 用于治疗癌症的双功能化合物
CN107531668B (zh) 治疗性哒嗪化合物及其用途
CN107108512B (zh) 治疗性化合物及其用途
CN109476641A (zh) Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
WO2013007768A1 (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
CN109219604A (zh) 四氢异喹啉雌激素受体调节剂及其用途
KR20130101044A (ko) 피리디논/피라지논, 그의 제조 방법 및 사용 방법
KR20140009259A (ko) 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
EP4185386B1 (en) Heterocyclic inhibitors of tead for treating cancer
TW201702232A (zh) 經取代之喹唑啉化合物及其使用方法
US12110276B2 (en) Pyrazolo compounds and methods of use thereof
KR20260023023A (ko) Wrn 억제제
WO2016001341A1 (en) Sulfonylaminopyridine compounds, compositions and methods of use
HK40068906A (en) Bifunctional compounds
EP4308573B1 (en) Cyclic compounds and methods of using same
WO2016091916A1 (en) Pyrazolylaminopurines as itk inhibitors
HK40071773A (en) Bifunctional compounds for the treatment of cancer
HK40110091A (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
CN119768401A (zh) 双环四氢硫氮杂䓬衍生物
HK40127987A (en) Cyclic compounds and methods of using same
CN117120447A (zh) 环状化合物和其使用方法
HK40110710A (en) Therapeutic indazole compounds and methods of use in the treatment of cancer
JP2025526727A (ja) 二環式テトラヒドロチアゼピン誘導体
HK40102447A (en) Bicyclic tetrahydroazepine derivatives for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068906

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220607